These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 14669536

  • 21. [Adverse effects of tamoxifen on the female genital tract].
    Anteby E, Yagel S, Zacut D, Palti Z, Hochner-Celnikier D.
    Harefuah; 1993 Nov 01; 125(9):267-70, 327. PubMed ID: 8253418
    [Abstract] [Full Text] [Related]

  • 22. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
    Bland AE, Calingaert B, Secord AA, Lee PS, Valea FA, Berchuck A, Soper JT, Havrilesky L.
    Gynecol Oncol; 2009 Jan 01; 112(1):150-4. PubMed ID: 18937966
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Gynaecological aspects of tamoxifen treatment in breast cancer patients.
    Obwegeser R, Auerbach L, Kubista E.
    Cancer Treat Rev; 1997 Jan 01; 23(5-6):289-304. PubMed ID: 9465881
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Reproductive tract pathology in asymptomatic women treated with tamoxifen.
    Yüce K, Tuncer ZS, Oncüloğlu C, Ayhan A, Baltali E, Güier N.
    Eur J Gynaecol Oncol; 2001 Jan 01; 22(6):466-8. PubMed ID: 11874085
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Co-occurrence of atypical endometriosis, subserous uterine leiomyomata, sactosalpinx, serous cystadenoma and bilateral hemorrhagic corpora lutea in a perimenopausal adipose patient taking tamoxifen (20 mg/day) for invasive lobular breast cancer.
    Ebert AD, Rosenow G, David M, Mechsner S, Magalov IS, Papadopoulos T.
    Gynecol Obstet Invest; 2008 Jan 01; 66(3):209-13. PubMed ID: 18645252
    [Abstract] [Full Text] [Related]

  • 33. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
    Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O'Shaughnessy JA.
    Breast Cancer Res Treat; 2009 Aug 01; 116(3):521-7. PubMed ID: 19139988
    [Abstract] [Full Text] [Related]

  • 34. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J.
    J Clin Oncol; 2006 Aug 20; 24(24):3991-6. PubMed ID: 16921052
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG.
    Ann N Y Acad Sci; 2006 Nov 20; 1089():127-42. PubMed ID: 17261762
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M.
    Clin Calcium; 2004 Oct 20; 14(10):105-10. PubMed ID: 15577140
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.